Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) (. gefitinib) currently remain the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) with activating EGFR mutation. | MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer